2 May 2025 - In Korea, Eli Lilly and Novo Nordisk are pushing for national health insurance coverage for their diabetes drugs Mounjaro and Ozempic, which have demonstrated benefits in blood sugar control and weight loss.

Korea Biomedical Review has learned on Friday that Lilly Korea is applying for health insurance coverage for Mounjaro (tirzepatide) for the indication of diabetes. The company is in discussions with the Health Insurance Review and Assessment Service (HIRA), and the agenda is currently under review by a subcommittee before being submitted to the Pharmaceutical Reimbursement Evaluation Committee (PREC).

Read Korea Biomedical Review article